Healthcare Edge and Exec Edge are please to provide complete video coverage of the third annual Palm Beach CorpGov Forum, which was held on Nov. 8, featuring a full day of panels and fireside chats. The event was composed of over...

PE Edge and Exec Edge are please to provide complete video coverage of the third annual Palm Beach CorpGov Forum, which was held on Wednesday, Nov. 8, featuring a full day of panels and fireside chats. The event was composed of...

The new book for aspiring day traders uses honesty to dispel myths and discourage anyone looking for overnight success. By Exec Edge Editorial Staff The world of day-trading is often perceived as a high-stakes gamble, with sensational stories of overnight...

By Karen E. Roman Alladapt Immunotherapeutics, Inc., a biopharmaceutical company developing treatment for Immunoglobulin E-mediated food allergy, said it received fast track designation by the U.S. Food and Drug Administration for ADP101, its multi-food oral immunotherapy. ADP101 is designed to...

IPO Edge hosted a fireside chat with Chief Executive Officer Michael Seifert of PublicSq (NYSE: PSQH) at the 3rd Annual Palm Beach CorpGov Forum in West Palm Beach, Florida. Mr. Seifert was joined by IPO Edge Editor-in-Chief John Jannarone and they...

By PE Edge Editorial Staff Hodes Weill & Associates and Cornell University published their annual Institutional Real Estate Allocations Monitor on real estate in institutional portfolios and the effects of institutional allocation tendencies on the investment management sector. The study...

By Exec Edge Editorial Staff Iran’s interference in Iraq’s internal politics has been pernicious and growing since the fall of Saddam Hussein in 2003. The Council on Foreign Relations writes that Iran has ties to more than a dozen political...

    By Healthcare Edge Editorial Staff Octave Bioscience, Inc., a company offering treatment for multiple sclerosis and other neurodegenerative diseases, said it has received a $10 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The...

  By Karen E. Roman SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage company developing a fully-human treatment to delay the progress of type 1 diabetes, said its net loss narrowed in the third quarter. The net loss was $5.1 million,...

By Thomas S. Green Swiss athletic brand On Holding AG (NYSE: ONON) raised full-year sales guidance after posting another record quarter, boosted by strength in footwear, apparel and accessories. The Zurich-based company said net sales rose 46.5% to CHF 480.5...